Apogee Therapeutics (APGE) Operating Income (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Operating Income data on file, last reported at -$82.8 million in Q1 2026.

• Quarterly Operating Income fell 31.18% year-over-year to -$82.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$73.3 million (down 16.12% YoY) and the FY2025 annual result came in at -$53.7 million, down 40.32% from the prior year.
• Operating Income eased to -$82.8 million in Q1 2026 per APGE's latest filing, from $153.9 million in the prior quarter.
• Across five years, Operating Income topped out at $153.9 million in Q4 2025 and bottomed at -$82.8 million in Q1 2026.
• The 5-year median for Operating Income is -$21.6 million (2023), against an average of -$13.7 million.
• Peak annual rise in Operating Income reached 371.02% in 2023, while the deepest fall reached 939.92% in 2023.
• Tracing APGE's Operating Income over 5 years: stood at -$14.1 million in 2022, then surged by 371.02% to $38.2 million in 2023, then jumped by 168.88% to $102.7 million in 2024, then soared by 49.76% to $153.9 million in 2025, then slumped by 153.79% to -$82.8 million in 2026.
• Per Business Quant, the three latest APGE Operating Income figures stand at -$82.8 million (Q1 2026), $153.9 million (Q4 2025), and -$71.3 million (Q3 2025).

Peer Comparison